Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support

Deborah Gleeson, James Scheibner, Dianne Nicol

Research output: Contribution to journalComment/debate

1 Citation (Scopus)
23 Downloads (Pure)

Abstract

"The Australian Government should review its position and support intellectual property waivers in the pandemic accord"

Throughout the coronavirus disease 2019 (COVID-19) pandemic, inequities in access to COVID-19 vaccines, diagnostics and therapeutics have been vast and persistent. By the end of 2022, only 26% of people in low income countries had received a COVID-19 vaccine dose. Less than one in 50 of the three billion diagnostic tests administered globally by March 2022 were performed in low income countries. Further, low and middle income countries have had very little access to therapeutics, particularly antivirals such as nirmatrelvir–ritonavir (Paxlovid, Pfizer) and molnupiravir (Lagevrio, Merck Sharpe & Dohme)...
Original languageEnglish
Pages (from-to)46-48
Number of pages3
JournalMedical Journal of Australia
Volume219
Issue number2
Early online date11 Jun 2023
DOIs
Publication statusPublished - Jul 2023

Keywords

  • COVID-19
  • Global health
  • Health policy
  • Intellectual property
  • Pharmaceuticals
  • Public health
  • World Health Organization

Fingerprint

Dive into the research topics of 'Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support'. Together they form a unique fingerprint.

Cite this